| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-05-18 09:02:16 UTC |
|---|
| Update Date | 2022-03-07 02:49:11 UTC |
|---|
| HMDB ID | HMDB0001937 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Salbutamol |
|---|
| Description | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma |
|---|
| Structure | CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1 InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Proventil | ChEBI | | (L)-Albuterol | HMDB | | 1-(Tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol | HMDB | | 2-(Tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol | HMDB | | 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol | HMDB | | Aerolin | HMDB | | Albuterol | HMDB | | Almotex | HMDB | | Alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol | HMDB | | Alti-salbutamol | HMDB | | Anebron | HMDB | | Arubendol-salbutamol | HMDB | | Asmadil | HMDB | | Asmanil | HMDB | | Asmasal | HMDB | | Asmatol | HMDB | | Asmaven | HMDB | | Asmidon | HMDB | | Asmol | HMDB | | Asmol uni-dose | HMDB | | Asthalin | HMDB | | Broncho-spray | HMDB | | Broncovaleas | HMDB | | Bronter | HMDB | | Bugonol | HMDB | | Bumol | HMDB | | Butamol | HMDB | | Buto-asma | HMDB | | Butohaler | HMDB | | Butotal | HMDB | | Butovent | HMDB | | Buventol | HMDB | | Cobutolin | HMDB | | Dilatamol | HMDB | | DL-Albuterol | HMDB | | DL-N-Tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine | HMDB | | DL-Salbutamol | HMDB | | Farcolin | HMDB | | Gerivent | HMDB | | Grafalin | HMDB | | Levalbuterol | HMDB | | Libretin | HMDB | | Medolin | HMDB | | Mozal | HMDB | | Novosalmol | HMDB | | Parasma | HMDB | | Pneumolat | HMDB | | Proventil hfa | HMDB | | Proventil inhaler | HMDB | | R-Salbutamol | HMDB | | Respax | HMDB | | Respolin | HMDB | | Sabutal | HMDB | | Salamol | HMDB | | Salbetol | HMDB | | Salbron | HMDB | | Salbu-basf | HMDB | | Salbu-fatol | HMDB | | Salbuhexal | HMDB | | Salbulin | HMDB | | Salbupur | HMDB | | Salbusian | HMDB | | Salbutalan | HMDB | | Salbutamol free base | HMDB | | Salbutamol sulfate | HMDB | | Salbutamol sulphate | HMDB | | Salbutamolum | HMDB | | Salbutan | HMDB | | Salbutol | HMDB | | Salbuven | HMDB | | Salbuvent | HMDB | | Sallbupp | HMDB | | Salmaplon | HMDB | | Salomol | HMDB | | Salvent | HMDB | | Saventol | HMDB | | Servitamol | HMDB | | Spreor | HMDB | | Sultanol | HMDB | | Sultanol N | HMDB | | Suprasma | HMDB | | Suxar | HMDB | | Theosal | HMDB | | Tobybron | HMDB | | Vencronyl | HMDB | | Ventamol | HMDB | | Ventilan | HMDB | | Ventiloboi | HMDB | | Ventodisks | HMDB | | Ventolin | HMDB | | Ventolin inhaler | HMDB | | Ventolin rotacaps | HMDB | | Ventoline | HMDB | | Volare albuterol hfa | HMDB | | Volare easi-breathe | HMDB | | Volmax | HMDB | | Zaperin | HMDB | | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | HMDB | | Albuterol sulfate | HMDB |
|
|---|
| Chemical Formula | C13H21NO3 |
|---|
| Average Molecular Weight | 239.3107 |
|---|
| Monoisotopic Molecular Weight | 239.152143543 |
|---|
| IUPAC Name | 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol |
|---|
| Traditional Name | salbutamol |
|---|
| CAS Registry Number | 18559-94-9 |
|---|
| SMILES | CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1 |
|---|
| InChI Identifier | InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3 |
|---|
| InChI Key | NDAUXUAQIAJITI-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzyl alcohols |
|---|
| Direct Parent | Benzyl alcohols |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzyl alcohol
- Phenol
- Aralkylamine
- 1-hydroxy-2-unsubstituted benzenoid
- Secondary alcohol
- 1,2-aminoalcohol
- Secondary amine
- Secondary aliphatic amine
- Hydrocarbon derivative
- Alcohol
- Aromatic alcohol
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 157 - 158 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 2.15 g/L | Not Available | | LogP | 1.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.83 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.343 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.27 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 152.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Salbutamol,1TMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C)C1=CC=C(O)C(CO)=C1 | 2023.4 | Semi standard non polar | 33892256 | | Salbutamol,1TMS,isomer #2 | CC(C)(C)NCC(O)C1=CC=C(O)C(CO[Si](C)(C)C)=C1 | 2112.8 | Semi standard non polar | 33892256 | | Salbutamol,1TMS,isomer #3 | CC(C)(C)NCC(O)C1=CC=C(O[Si](C)(C)C)C(CO)=C1 | 2054.7 | Semi standard non polar | 33892256 | | Salbutamol,1TMS,isomer #4 | CC(C)(C)N(CC(O)C1=CC=C(O)C(CO)=C1)[Si](C)(C)C | 2224.3 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO)=C1 | 1915.8 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #2 | CC(C)(C)NCC(O[Si](C)(C)C)C1=CC=C(O)C(CO[Si](C)(C)C)=C1 | 1981.3 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #3 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O)C(CO)=C1)[Si](C)(C)C | 2222.5 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #4 | CC(C)(C)NCC(O)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1 | 2031.1 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #5 | CC(C)(C)N(CC(O)C1=CC=C(O)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2245.4 | Semi standard non polar | 33892256 | | Salbutamol,2TMS,isomer #6 | CC(C)(C)N(CC(O)C1=CC=C(O[Si](C)(C)C)C(CO)=C1)[Si](C)(C)C | 2196.9 | Semi standard non polar | 33892256 | | Salbutamol,3TMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1 | 1921.0 | Semi standard non polar | 33892256 | | Salbutamol,3TMS,isomer #2 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO)=C1)[Si](C)(C)C | 2188.6 | Semi standard non polar | 33892256 | | Salbutamol,3TMS,isomer #3 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2242.2 | Semi standard non polar | 33892256 | | Salbutamol,3TMS,isomer #4 | CC(C)(C)N(CC(O)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2232.1 | Semi standard non polar | 33892256 | | Salbutamol,4TMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2249.8 | Semi standard non polar | 33892256 | | Salbutamol,4TMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2252.4 | Standard non polar | 33892256 | | Salbutamol,4TMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C)C1=CC=C(O[Si](C)(C)C)C(CO[Si](C)(C)C)=C1)[Si](C)(C)C | 2116.4 | Standard polar | 33892256 | | Salbutamol,1TBDMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O)C(CO)=C1 | 2286.6 | Semi standard non polar | 33892256 | | Salbutamol,1TBDMS,isomer #2 | CC(C)(C)NCC(O)C1=CC=C(O)C(CO[Si](C)(C)C(C)(C)C)=C1 | 2330.6 | Semi standard non polar | 33892256 | | Salbutamol,1TBDMS,isomer #3 | CC(C)(C)NCC(O)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO)=C1 | 2308.2 | Semi standard non polar | 33892256 | | Salbutamol,1TBDMS,isomer #4 | CC(C)(C)N(CC(O)C1=CC=C(O)C(CO)=C1)[Si](C)(C)C(C)(C)C | 2478.9 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO)=C1 | 2445.5 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #2 | CC(C)(C)NCC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O)C(CO[Si](C)(C)C(C)(C)C)=C1 | 2470.2 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #3 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O)C(CO)=C1)[Si](C)(C)C(C)(C)C | 2730.3 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #4 | CC(C)(C)NCC(O)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1 | 2537.4 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #5 | CC(C)(C)N(CC(O)C1=CC=C(O)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 2744.9 | Semi standard non polar | 33892256 | | Salbutamol,2TBDMS,isomer #6 | CC(C)(C)N(CC(O)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO)=C1)[Si](C)(C)C(C)(C)C | 2727.9 | Semi standard non polar | 33892256 | | Salbutamol,3TBDMS,isomer #1 | CC(C)(C)NCC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1 | 2644.6 | Semi standard non polar | 33892256 | | Salbutamol,3TBDMS,isomer #2 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO)=C1)[Si](C)(C)C(C)(C)C | 2926.9 | Semi standard non polar | 33892256 | | Salbutamol,3TBDMS,isomer #3 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 2945.8 | Semi standard non polar | 33892256 | | Salbutamol,3TBDMS,isomer #4 | CC(C)(C)N(CC(O)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 2973.8 | Semi standard non polar | 33892256 | | Salbutamol,4TBDMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 3136.2 | Semi standard non polar | 33892256 | | Salbutamol,4TBDMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 2964.8 | Standard non polar | 33892256 | | Salbutamol,4TBDMS,isomer #1 | CC(C)(C)N(CC(O[Si](C)(C)C(C)(C)C)C1=CC=C(O[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C | 2549.4 | Standard polar | 33892256 |
|
|---|
| General References | - Fayon M, Dumas De La Roque E, Berger P, Begueret H, Ousova O, Molimard M, Marthan R: Increased relaxation of immature airways to beta2-adrenoceptor agonists is related to attenuated expression of postjunctional smooth muscle muscarinic M2 receptors. J Appl Physiol (1985). 2005 Apr;98(4):1526-33. Epub 2004 Dec 3. [PubMed:15579574 ]
- Yoshihara S, Yamada Y, Abe T, Kashimoto K, Linden A, Arisaka O: Long-lasting smooth-muscle relaxation by a novel PACAP analogue in human bronchi. Regul Pept. 2004 Dec 15;123(1-3):161-5. [PubMed:15518907 ]
|
|---|